DENVER, Jan. 30 /PRNewswire-FirstCall/ -- Myogen, Inc. (Nasdaq: MYOG), a
biopharmaceutical company focused on the discovery, development and
commercialization of small molecule therapeutics for the treatment of
cardiovascular disorders, today announced that J. William Freytag, President
and Chief Executive Officer, will present a corporate overview at the NASDAQ
US Small Cap Conference to be held in London, February 7-8, 2006.
The presentation will take place at 1:30 p.m. (GMT) on
Wednesday, February 8, 2006. There will be a live webcast of the
presentation, which will be accessible through a link posted on the investor
relations section of the Myogen website at http://investor.myogen.com/. The
webcast will be available for replay on Myogen's website through
February 28, 2006.
Myogen has two product candidates in late-stage clinical development:
ambrisentan for the treatment of patients with pulmonary arterial hypertension
(PAH) and darusentan for the treatment of patients with resistant hypertension
(RHTN). The Company, in collaboration with Novartis, also conducts a target
and drug discovery research program focused on the development of
disease-modifying drugs for the treatment of chronic heart failure and related
cardiovascular disorders. Please visit the company's website at
http://www.myogen.com.
Safe Harbor Statement
The anticipated presentation will contain forward-looking statements that
involve significant risks and uncertainties, including those to be discussed
in the presentation and others that can be found in the "Risk Factors" section
of Myogen's Form 10-K for the year ended December 31, 2004 and Myogen's
periodic reports on Form 10-Q and Form 8-K. Myogen does not undertake any
obligation to update any forward-looking statements contained in the
anticipated presentation as a result of new information, future events or
otherwise. The company cautions investors not to place undue reliance on the
forward-looking statements contained in this press release or the
presentation. No forward-looking statement can be guaranteed and actual
events and results may differ materially from those projected.
SOURCE Myogen, Inc.
 back to top
Related links:
http://www.myogen.com
http://investor.myogen.com
CONTACT:
Derek K. Cole, Director, Investor Relations
of Myogen, Inc., +1-303-464-3986, derek.cole@myogen.com
|
